| Publications | PubMed=2751270
Chan H.S.L., Canton M.D., Gallie B.L.
Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines.
Anticancer Res. 9:469-474(1989) PubMed=2090524; DOI=10.1111/j.1432-0436.1990.tb00479.x
Griegel S., Heise K., Kindler-Rohrborn A., Rajewsky M.F.
In vitro differentiation of human retinoblastoma cells into neuronal phenotypes.
Differentiation 45:250-257(1990) PubMed=2365495; DOI=10.1002/ijc.2910460123
Griegel S., Hong C., Frotschl R., Hulser D.F., Greger V., Horsthemke B., Rajewsky M.F.
Newly established human retinoblastoma cell lines exhibit an 'immortalized' but not an invasive phenotype in vitro.
Int. J. Cancer 46:125-132(1990) PubMed=1682862; DOI=10.1016/S0161-6420(91)32134-1
Chan H.S.L., Thorner P.S., Haddad G., Gallie B.L.
Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression.
Ophthalmology 98:1425-1431(1991) PubMed=11520568; DOI=10.1016/S0165-4608(01)00427-7
Chen D., Gallie B.L., Squire J.A.
Minimal regions of chromosomal imbalance in retinoblastoma detected by comparative genomic hybridization.
Cancer Genet. Cytogenet. 129:57-63(2001) PubMed=15326157; DOI=10.1167/iovs.04-0140
DiCiommo D.P., Duckett A., Burcescu I., Bremner R., Gallie B.L.
Retinoblastoma protein purification and transduction of retina and retinoblastoma cells using improved alphavirus vectors.
Invest. Ophthalmol. Vis. Sci. 45:3320-3329(2004) PubMed=18036396; DOI=10.1016/j.cancergencyto.2007.08.014
Paderova J., Orlic-Milacic M., Yoshimoto M., da Cunha Santos G., Gallie B.L., Squire J.A.
Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses.
Cancer Genet. Cytogenet. 179:102-111(2007) PubMed=23498719; DOI=10.1016/S1470-2045(13)70045-7
Rushlow D.E., Mol B.M., Kennett J.Y., Yee S., Pajovic S., Theriault B.L., Prigoda-Lee N.L., Spencer C., Dimaras H., Corson T.W., Pang R., Massey C., Godbout R., Jiang Z., Zacksenhaus E., Paton K., Moll A.C., Houdayer C., Raizis A., Halliday W., Lam W.L., Boutros P.C., Lohmann D.R., Dorsman J.C., Gallie B.L.
Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.
Lancet Oncol. 14:327-334(2013) PubMed=27115612; DOI=10.1371/journal.pone.0153323; PMCID=PMC4846005
Kooi I.E., Mol B.M., Massink M.P.G., de Jong M.C., de Graaf P., van der Valk P., Meijers-Heijboer H., Kaspers G.J.L., Moll A.C., te Riele H., Cloos J., Dorsman J.C.
A meta-analysis of retinoblastoma copy numbers refines the list of possible driver genes involved in tumor progression.
PLoS ONE 11:E0153323-E0153323(2016) PubMed=30584916; DOI=10.1016/j.yexcr.2018.12.018
Schwermer M., Hiber M., Dreesmann S., Rieb A., Theissen J., Herold T., Schramm A., Temming P., Steenpass L.
Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Exp. Cell Res. 375:92-99(2019) PubMed=32123578; DOI=10.1038/s41420-020-0237-8; PMCID=PMC7026052
Aubry A., Yu T., Bremner R.
Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy.
Cell Death Discov. 6:2.1-2.12(2020) |
|---|
